Johnson, Amber http://orcid.org/0000-0002-6202-6113
Ng, Patrick Kwok-Shing
Kahle, Michael
Castillo, Julia
Amador, Bianca
Wang, Yujia http://orcid.org/0000-0002-5264-521X
Zeng, Jia
Holla, Vijaykumar
Vu, Thuy http://orcid.org/0000-0002-8163-6144
Su, Fei
Kim, Sun-Hee
Conway, Tara
Jiang, Xianli
Chen, Ken http://orcid.org/0000-0003-4013-5279
Shaw, Kenna R. Mills
Yap, Timothy A. http://orcid.org/0000-0002-2154-3309
Rodon, Jordi
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Meric-Bernstam, Funda http://orcid.org/0000-0001-6816-6072
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP150535)
UTHealth | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston (UL1TR003167)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA016672)
Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Article History
Received: 7 December 2022
Accepted: 3 July 2023
First Online: 15 July 2023
Competing interests
: MD Anderson receives licensing fees for our Precision Oncology Decision Support (PODS) database from Philips Healthcare, which support continued development of the system at MD Anderson. J.R. reports serving on the Advisory Board for Peptomyc, Kelun Pharmaceuticals/Klus Pharma, Ellipses Pharma, Molecular Partners, IONCTURA; Research Funding to his institution from Blueprint Medicines, Black Diamond Therapeutics, Merck Sharp & Dohme, Hummingbird, Yingli, Vall d’Hebron Institute of Oncology/Cancer Core Europe; Clinical Research to his institution from Novartis, Spectrum Pharmaceuticals, Symphogen, BioAlta, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GalxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bycicle Therapeutics, Merus, Curis, Bayer, AadiBioscience, Nuvation, ForeBio, BioMed Valley Discoveries, Loxo Oncology, Hutchinson MediPharma, Cellestia, Deciphera, Ideaya, Amgen, Tango Therapeutics, Mirati Linnaeus Therapeutics; Travel Reimbursement from European Society for Medical Oncology and Other from Vall d’Hebron Institute of Oncology/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, Boxer Capital, LLC, Tang Advisors, LLC. G.B.M. reports SAB/Consultant fees from Amphista, Astex, AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, GSK, ImmunoMET, Infinity, Ionis, Leapfrog Bio, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Qureator, Roche, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals; Stock/Options/Financials from Bluedot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, SignalChem, Tarveda, Turbine; Licensed Technology from HRD assay to Myriad Genetics, DSP patents with Nanostring; Sponsored research from AstraZeneca. T.A.Y. reports Employment at University of Texas MD Anderson Cancer Center, where I am Medical Director of the Institute for Applied Cancer Science, which has a commercial interest in DDR and other inhibitors (IACS30380/ART0380 was licensed to Artios); Grant/Research support to his institution from Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, ImmuneSensor, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, Vivace and Zenithl Consultancy fees from AbbVie, AstraZeneca, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Athena, Atrin, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Clovis, Cybrexa, Diffusion, EMD Serono, F-Star, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Idience, Ignyta, I-Mab, ImmuneSensor, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Natera, Nexys, Novocure, OHSU, OncoSec, Ono Pharma, Pegascy, PER, Pfizer, Piper-Sandler, Prolynx, Repare, resTORbio, Roche, Schrodinger, Theragnostics, Varian, Versant, Vibliome, Xinthera, Zai Labs and ZielBio; he also holds stock in Seagen. F.M-B. reports Consulting fees from AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, Daiichi Sankyo Co. Ltd., DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., GT Apeiron, Genentech Inc., Harbinger Health, IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Protai Bio Ltd, Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, Zymeworks; has served on the Advisory Committee for Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Sanofi, Silverback Therapeutics, Spectrum Pharmaceuticals, Zentalis; has received Sponsored Research (to the institution) from Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc., Taiho Pharmaceutical Co.; has received Honoraria (speaking engagement) from Chugai Biopharmaceuticals and Travel reimbursement from European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Medical Oncology (ESMO). The remaining authors declare no competing interests.